HOME >> MEDICINE >> NEWS
Animal studies indicate new approach for treating end-stage skin and kidney cancers

New Orleans, La., March 26, 2001 Advanced skin and end-stage kidney cancer patients may have a better chance of survival with drugs developed from a new synthetic enzyme that significantly improves the effectiveness of existing interleukin-2 (IL-2) cancer therapy, based on research presented today at the American Association for Cancer Research 92nd Annual Meeting.

In animal studies conducted by researchers at the Huntsman Cancer Institute in Salt Lake City, UT, and MetaPhore Pharmaceuticals in St. Louis, MO, the synthetic enzyme M40403 showed an ability to reverse the extreme blood-pressure drop that is a common side effect of high-dosage IL-2 cancer therapy. The research also showed that the compound enhances the anti-cancer properties of IL-2 therapy.

IL-2 immunotherapy, which works by activating natural killer (NK) cells that have the ability to recognize and destroy many types of tumors, is an approved treatment for inoperable metastatic melanoma and metastatic renal cell carcinoma. About 80,000 cases of melanoma and renal cell carcinoma are diagnosed in the U.S. each year.

IL-2 use is limited, however, by potentially life threatening side effects, including hypotension, particularly at the high-dosage level indicated for these end-stage cancers. A majority of patients undergoing high-dosage IL-2 treatment currently either require intensive care unit (ICU) intervention and/or are unable to complete the full course of treatment.

Reseachers administered the synthetic enzyme, which mimics the action of a natural enzyme, superoxide dismutase (SOD), as a co-therapy with IL-2 in several animal models of advanced cancer. Previous studies have confirmed that the synthetic enzyme effectively reproduces the free-radical fighting properties of the natural SOD enzyme, which has been found to be deficient in cancer states.

When in excess, free radicals particularly superoxide anions have been shown to deactivate a class of molecules, calle
'"/>

Contact: Punnie Donohue
pdonohue@kupperparker.com
314-290-2014
Kupper Parker Communications
25-Mar-2001


Page: 1 2 3 4

Related medicine news :

1. Animal study shows link between nicotine and atrial flutter
2. Animal studies show stem cells might make biological pacemaker
3. Animal study suggests safer immunization approach to Alzheimers
4. Animal model, new grant, propel UB researchers forward in search for tinnitus treatment
5. Animal model shows early promise for SARS vaccine
6. Understanding Alzheimers disease: Animal research points to new direction for therapy
7. Animal studies prove hormone replacement therapy improves memory, report Pitt researchers
8. Animal-based nutrients linked with higher risk of stomach and esophageal cancers
9. Animal study show that heat-sensitive liposome improves chemotherapy delivery to tumors
10. Animal model shows pain and tissue injury in newborns alters nerve circuitry and reaction to pain later in life
11. AVANT Atherosclerosis Vaccine Raises HDL, Reduces Atherosclerosis In Vaccinated Animals

Post Your Comments:
(Date:9/4/2015)... ... September 04, 2015 , ... Scalability Experts (SE) announced that ... at this year’s Microsoft Worldwide Partner Conference that was held in Orlando, Florida. ... Winner for Data Platform services, the 2015 HP and Microsoft “Outstanding Frontline Partner” ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Mike Day, a ... 2007, will compete in the Ironman World Championships in Kona on October 10th. , ... incurred Traumatic Brain Injury (TBI) through combat and the cutting-edge treatments that restore their ...
(Date:9/4/2015)... ... September 04, 2015 , ... The conference program for the ... October 9-10, 2015 at the Diplomat Resort & Spa has been announced and ... researchers at the top of their field and will be presenting sessions such ...
(Date:9/4/2015)... ... 04, 2015 , ... Steven Winter Associates, Inc., (SWA) is ... selected for the Residential Award of Merit by the Connecticut Green Building Council ... a highly competitive field of submissions, the net-zero energy residence will be honored ...
(Date:9/4/2015)... ... September 04, 2015 , ... EMED ... today announced that it has entered into a multi-year agreement with Health City ... to bridge the link between American healthcare, Jamaican healthcare and Health City Cayman ...
Breaking Medicine News(10 mins):Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 2Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 4Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:South Glastonbury Home Selected for Award by Connecticut Green Building Council 2Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 2Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 3Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 4Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 5Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 6
(Date:9/4/2015)... 2015  Luminex Corporation (NASDAQ: LMNX ) today ... Global Healthcare Conference to be held September 16 - ... New York City . The ... on Friday, September 18, 2015.  The presentation will be webcast ... at http://www.luminexcorp.com . Simply log on to the web ...
(Date:9/4/2015)... September 4, 2015 According to ... (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) by Procedure (Therapeutic ... Product - Global Forecast to 2020", published by MarketsandMarkets, ... 2.5 Billion by 2020, growing at a CAGR of ... Browse 139 Tables and 45 F ...
(Date:9/4/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... the development of oral drug delivery systems, announced today ... & Renshaw 17 th Annual Global Investment Conference, ... York City .  Dr. Michael Berelowitz , ... September 9, 2015. Presentation Details: ...
Breaking Medicine Technology:Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference 2Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3
Cached News: